02142.HK_Providing professional financial news and data related to 02142.HK, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

HBM HOLDINGS-B (02142.HK): Expected Profit of USD62 Million–USD67 Million for H1 2026; Revenue Stood at Approximately USD101 Million in Corresponding Period Last Year

Tags：

HBM HOLDINGS-B 02142.HK positive profit alert

2026-07-24

HBM Holdings(02142.HK): IND Application of HBM7575 for Asthma Treatment Approved by NMPA

Tags：

HBM Holdings 02142.HK

2026-07-15

HBM HOLDINGS-B (02142.HK): NMPA Accepts IND Application of HBM7004 for Advanced Solid Tumors

Tags：

HBM HOLDINGS-B 02142.HK Clinical Trial

2026-06-10

HBM HOLDINGS-B (02142.HK): Preclinical Data Unveiled for First AI-Derived Candidate LET003, Showing Remarkable Fat Loss & Muscle Preservation Combined with Semaglutide

Tags：

HBM HOLDINGS-B 02142.HK preclinical data

2026-05-18

HBM HOLDINGS-B(02142.HK): Independent Non-executive Director Ye Xiaoping Under CSRC Case Investigation

Tags：

HBM HOLDINGS-B 02142.HK case filing notice

2026-05-13

HBM HOLDINGS-B(02142.HK) will spend HKD 10.27 million to repurchase 800 thousand shares on May 6, 2026

Tags：

HBM HOLDINGS-B 02142.HK

2026-05-06

HBM HOLDINGS-B (02142.HK): Bispecific Antibody HBM7575 Approved for Clinical Trial by NMPA

Tags：

HBM HOLDINGS-B 02142.HK investigational new drug

2026-03-09

Scan QR Code

Download App